This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, M. E.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, M. E.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2651-2655, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2651-2655.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Longitudinal Assessment of Antipneumococcal Susceptibility in the United States

Mark E. Jones,1* James A. Karlowsky,2 Renée Blosser-Middleton,2 Ian A. Critchley,2 Elena Karginova,2 Clyde Thornsberry,3 and Daniel F. Sahm2

Focus Technologies, Inc., 1217 KP Hilversum, The Netherlands,1 Focus Technologies, Inc., Herndon, Virginia 20171,2 Focus Technologies, Inc., Franklin, Tennessee, 370643

Received 27 June 2001/ Returned for modification 15 October 2001/ Accepted 2 May 2002

The prevalence of antimicrobial resistance among 4,940 U.S. pneumococcal isolates collected during 1999 was as follows: penicillin, 16.2%; amoxicillin-clavulanate, 12.2%; cefuroxime, 28.1%; ceftriaxone, 3.6%; trimethoprim-sulfamethoxazole, 30.3%; azithromycin, 21.4%; levofloxacin, 0.6%; and moxifloxacin, 0.1%. Compared to the previous 1997-1998 study (Jones et al., Antimicrob. Agents Chemother. 44:2645-2652, 2000), increases were noted for resistance to penicillin (3.7%; P < 0.001), amoxicillin-clavulanate (3.9%; P < 0.001), cefuroxime (5.7%; P < 0.001), azithromycin (2.4%; P = 0.014), trimethoprim-sulfamethoxazole (15.4%; P < 0.001), and levofloxacin (0.3%; P = 0.017). Resistance to ceftriaxone (0.1%; P = 0.809) and moxifloxacin (0.03%; P = 0.570) decreased. Concurrently, multidrug resistance increased (P < 0.001) from 6.3% to 11.3%.

* Corresponding author. Mailing address: Focus Technologies, Koninginneweg 11, 1217 KP Hilversum, The Netherlands. Phone: 31 35 625 7290. Fax: 31 35 625 7287. E-mail: mjones{at}focusanswers.com.

Antimicrobial Agents and Chemotherapy, August 2002, p. 2651-2655, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2651-2655.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Critchley, I. A., Brown, S. D., Traczewski, M. M., Tillotson, G. S., Janjic, N. (2007). National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study. Antimicrob. Agents Chemother. 51: 4382-4389 [Abstract] [Full Text]  
  • Sadowy, E., Izdebski, R., Skoczynska, A., Gniadkowski, M., Hryniewicz, W. (2005). High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland. Antimicrob. Agents Chemother. 49: 2126-2129 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., Sato, K. (2003). In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3750-3759 [Abstract] [Full Text]  
  • Davies, T. A., Goldschmidt, R., Pfleger, S., Loeloff, M., Bush, K., Sahm, D. F., Evangelista, A. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 52: 168-175 [Abstract] [Full Text]  
  • Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I., Karginova, E., Thornsberry, C., Sahm, D. F. (2003). Reinterpretation of Susceptibility Data Using Current NCCLS Breakpoint Criteria. Antimicrob. Agents Chemother. 47: 830-830 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»